Clinical Trials Browser

OTHER × Neoplasms × dabrafenib × Clear all

NCT02693535 2026-05-29

TAPUR

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT06978400 2025-05-18

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

Phase 2 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

Neoplasms

NCT05876806 2023-11-30

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Phase 2 Unknown

Neoplasms

NCT02858921 2023-08-30

Neo Trio

Phase 2 Unknown

Melanoma, Neoplasms

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

Neoplasms